139953-73-4

Usage

Uses

Used in Pharmaceutical Industry:
Cyclazosin is used as a pharmaceutical compound for its potential therapeutic applications. Its unique structure allows it to interact with specific biological targets, making it a candidate for the development of new drugs to treat various medical conditions.
Used in Chemical Research:
In the field of chemical research, cyclazosin serves as a valuable compound for studying the properties and reactivity of monocarboxylic acid amides. Its synthesis and characterization can provide insights into the behavior of similar compounds and contribute to the advancement of chemical knowledge.
Used in Material Science:
Cyclazosin's unique structure and properties may also find applications in material science. It could potentially be used in the development of new materials with specific properties, such as improved strength, flexibility, or chemical resistance, depending on its interaction with other compounds and its stability under various conditions.

InChI:InChI=1/C23H27N5O4/c1-30-19-12-14-15(13-20(19)31-2)25-23(26-21(14)24)28-10-9-27(16-6-3-4-7-17(16)28)22(29)18-8-5-11-32-18/h5,8,11-13,16-17H,3-4,6-7,9-10H2,1-2H3,(H2,24,25,26)/t16-,17+/m0/s1

Upstream product

• 23680-84-4 2-chloro-6,7-dimethoxyquinazolin-4-amine 
• 527-69-5 2-furancarbonyl chloride 
• 944767-72-0 (-)-6,7-dimethoxy-2-[(4aS,8aR)-octahydroquinoxalin-1(2H)-yl]quinazolin-4-amine 
• 32044-25-0 (+/-)-trans-decahydroquinoxaline 

Relevant academic research and scientific papers

Synthesis and α1-adrenoceptor antagonist activity of derivatives and isosters of the furan portion of (+)-cyclazosin

α1-Adrenoceptor selective antagonists are crucial in investigating the role and biological functions of α1-adrenoceptor subtypes. We synthesized and studied the α1-adrenoceptor blocking properties of new molecules structur

Structure-Activity Relationships in Prazosin-Related Compounds. 2. Role of the Piperazine Ring on α-Blocking Activity

Several prazosin-related compounds have been synthesized and evaluated for their blocking activity toward α-adrenoreceptors.The structural modification performed on the prazosin structure included the replacement of the piperazine ring with 2,3-dialkylpiperazine or 1,2-cyclohexanediamine moieties to characterize a lipophilic binding pocket in the α1 adrenoreceptor surface.Cyclohexanediamine derivatives 3-6 were almost devoid of potency and selectivity, whereas dialkylpiperazine compounds 7-14 showed high affinity and selectivity toward α1-adrenoreceptors.The cis derivative 13 (cyclazosin) was the most potent and selective with an α1/α2 selectivity ratio value of 7800.The particular trend of antagonist activity within cis/trans stereoisomeric compounds not only supports the presence of a lipophilic binding area on α1-adrenoreceptor surface but also suggests that the lipophilic pocket is endowed with a well-defined size and spatial orientation.The most active compound of the series, 13, was tested also in vivo for antihypertensive activity on spontaneously hypertensive rats.It showed an interesting long-lasting hypotensive effect, very similar to that of doxazosin, which was statistically significant 12 h after oral administration.